澳门赌场招聘-赌场有哪些_免费百家乐追号软件_全讯网最新资讯网址 (中国)·官方网站

In the Media

[China Daily Global] New cell theory offers hope for tumor treatment

Source: China Daily Global 2022-07-08 Page 006 Written by: ZHENG CAIXIONG Edited by: Wang Dongmei

A senior Chinese scientist has recently elaborated on a theory on effector immune cell deployment (EICD) in the immune system as a new mechanism for combating tumors.

The breakthrough offers a theoretical basis for re-evaluating anti-tumor mechanisms and should help with the formulation of more accurate immunotherapy strategies, according to Song Erwei, an academician at the Chinese Academy of Sciences.

Song and his team recently published their results titled "Turning cold tumors hot: from molecular mechanisms to clinical applications" in the May edition of Elsevier journal Trends in Immunology.

According to Song, who is also president of the Sun Yat-sen Memorial Hospital at Guangzhou's Sun Yat-sen University, the new theory can be applied to the diagnosis and treatment of all kinds of tumors.

The process of tumorigenesis (the production and formation of tumors) arises from a struggle between the tumor and the host immune system. Song said the new concept of effective immune cell array is an important theory in tumor ecology.

"Many people believe that long-term use of Cordyceps sinensis (a fungus that infects certain caterpillars) and Ganoderma lucidum (the Reishi mushroom) by tumor patients helps enhance immunity against tumors," he said.

But the term "immunity", especially as used by the public, is a very broad concept, which essentially refers to the ability of the immune system to protect the body from illnesses, he added.

"However, the body's immune system is specific and responds differently to different substances. Immunity against bacterial and viral infections may not prove useful in fighting tumors," Song said.

"Therefore, the immunity enhanced by eating Ganoderma lucidum and Cordyceps sinensis is not necessarily anti-tumor immunity."

Clinicians have come to use the concept of "cold" and "hot" tumors to evaluate the strength of anti-tumor immunity in recent years, he said. It is generally believed that a "cold" tumor is characterized by little or no T-cell infiltration of the tumor. Patients have a poor prognosis for survival and do not benefit from immunotherapy.

Correspondingly, a "hot" tumor that is rich in T-cell infiltration responds to immunotherapy and presents a good prognosis for survival.

Effector immune cells are the cells in the immune system that fight tumor cells, and these include adaptively immune T-cells and naturally immune Natural Killer cells.

"The immune system deploys against tumor cells through lymph nodes, peripheral blood and the tumor's microenvironment," Song said, adding that this so-called "control deployment" precisely reflects the way the human immune system marshals its forces to fight tumor cells at the cellular and molecular levels.

"In the future, based on the mechanism of EICD, doctors will be able to accurately diagnose the immune phenotype of tumors and generate a corresponding diagnosis and treatment and drug systems. Then, they can screen new treatment targets and take specific treatment measures to transform 'cold' tumors into 'hot' tumors," Song said.

Combined with immune checkpoint therapy, EICD will help strengthen tumor immunity in cancer patients and improve both the effect of treatment and the survival period of patients, he added.

Link to the report: https://epaper.chinadaily.com.cn/a/202207/08/WS62c7883ca3109375516ed778.html

百家乐技巧技巧| 百家乐官网小路规则| 大发888游戏官方网站| 菲律宾云顶国际| 百家乐官网赌博大揭密| 百家乐园游戏庄闲| 百家乐画哪个路单| 崇明县| 百家乐娱乐城玩法| 德州扑克官方下载| 信誉百家乐官网博彩网| 玩百家乐高手支招篇| 现金棋牌网站| 菲彩百家乐官网的玩法技巧和规则 | 百家乐官网网上赌局| 网页百家乐的玩法技巧和规则| 百家乐官网稳赚打法| 宝马会百家乐官网娱乐城| 五星百家乐的玩法技巧和规则| 海兴县| 百家乐平技巧| 永利百家乐官网游戏| 百家乐赌场走势图| 桂东县| 网上百家乐软件大全酷| 玩百家乐官网五湖四海娱乐城| 新利百家乐的玩法技巧和规则| 至尊百家乐官网20130402| 百家乐官网视频游戏网址| 博天堂百家乐官网| 百家乐官网天下第一缆| 威尼斯人娱乐城反水| 在线百家乐官网博彩| 日博bet365| 百家乐六手变化混合赢家打法| 真人百家乐官网平台排行| 大发888真人网站| 百家乐官网赢钱面面观| 爱拼网| 百家乐输钱的原因| 百家乐官网开发公司|